We are live on
!
Find out more
Boston Partners Portfolio holdings
AUM
$113B
1-Year Est. Return
38.87%
This Fund
S&P 500
This Quarter
Est. Return
-14.15%
1 Year Est. Return
+38.87%
3 Year Est. Return
+108.29%
5 Year Est. Return
+142.95%
10 Year Est. Return
+500.61%
AUM
$69.6B
AUM Growth
-$16.5B
(-19%)
Cap. Flow
-$3.3B
Cap. Flow
% of AUM
-4.75%
Top 10 Holdings %
Top 10 Hldgs %
17.71%
Holding
779
New
83
Increased
294
Reduced
313
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$753M |
| 2 |
Marathon Petroleum
MPC
|
+$374M |
| 3 |
Target
TGT
|
+$361M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$299M |
| 5 |
Huntington Bancshares
HBAN
|
+$242M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ANDV
Andeavor
ANDV
|
+$1.05B |
| 2 |
Merck
MRK
|
+$702M |
| 3 |
Bank of America
BAC
|
+$542M |
| 4 |
Oracle
ORCL
|
+$528M |
| 5 |
Steel Dynamics
STLD
|
+$499M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 26.74% |
| 2 | Healthcare | 14.95% |
| 3 | Industrials | 13.38% |
| 4 | Technology | 12.24% |
| 5 | Energy | 6.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Novartis
NVS
$294B
| $605M | 0.87% |
7,864,222
+1,629,187
| +26% | +$127M |
|
27
McKesson
MCK
$104B
| $591M | 0.85% |
5,349,038
-684,812
| -11% | -$85.4M |
|
|
28
Huntington Bancshares
HBAN
$34.1B
| $589M | 0.85% |
49,450,631
+17,411,546
| +54% | +$242M |
|
29
American International
AIG
$40.1B
| $586M | 0.84% |
14,867,095
+1,797,115
| +14% | +$78.5M |
|
|
30
Oracle
ORCL
$438B
| $563M | 0.81% |
12,461,499
-11,022,414
| -47% | -$528M |
|
|
Y
31
DELISTED
Alleghany Corp
Y
| $562M | 0.81% |
902,201
+13,861
| +2% | +$8.54M |
|
32
Delta Air Lines
DAL
$53.4B
| $552M | 0.79% |
11,061,116
-2,266,748
| -17% | -$123M |
|
|
RDS.A
33
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $541M | 0.78% |
9,283,911
-332,260
| -3% | -$20.6M |
|
34
Everest Group
EG
$14.5B
| $535M | 0.77% |
2,456,873
+79,444
| +3% | +$17.3M |
|
35
TE Connectivity
TEL
$58.8B
| $532M | 0.77% |
7,039,632
-3,182,117
| -31% | -$245M |
|
36
Aon
AON
$74.2B
| $528M | 0.76% |
3,634,161
+907,862
| +33% | +$141M |
|
37
DXC Technology
DXC
$1.76B
| $511M | 0.73% |
9,618,304
-4,246,898
| -31% | -$293M |
|
38
Gilead Sciences
GILD
$185B
| $502M | 0.72% |
8,018,715
-360,174
| -4% | -$25.2M |
|
39
Eaton
ETN
$162B
| $501M | 0.72% |
7,290,529
-329,382
| -4% | -$24.6M |
|
40
SL Green Realty
SLG
$4.1B
| $500M | 0.72% |
6,525,890
+773,987
| +13% | +$68.5M |
|
41
Cummins
CMI
$79B
| $488M | 0.7% |
3,654,138
-1,737,404
| -32% | -$245M |
|
42
Coca-Cola Europacific Partners
CCEP
$47.4B
| $481M | 0.69% |
10,500,329
-95,046
| -0.9% | -$4.4M |
|
|
VMRK
43
Vivmark Residential
VMRK
$26.1B
| $427M | 0.61% |
6,475,134
-57,488
| -0.9% | -$3.86M |
|
44
FMC
FMC
$1.33B
| $427M | 0.61% |
6,651,958
+1,930,108
| +41% | +$135M |
|
45
Nutrien
NTR
$34.9B
| $424M | 0.61% |
9,028,316
+155,876
| +2% | +$8.13M |
|
46
Dover
DOV
$27.2B
| $420M | 0.6% |
5,913,428
+225,478
| +4% | +$18.4M |
|
47
ConocoPhillips
COP
$156B
| $419M | 0.6% |
6,727,301
-1,638,147
| -20% | -$111M |
|
48
The Mosaic Company
MOS
$7.55B
| $416M | 0.6% |
14,243,641
+4,814,199
| +51% | +$158M |
|
49
Labcorp
LH
$27.3B
| $413M | 0.59% |
3,805,428
-1,391,918
| -27% | -$186M |
|
50
Southwest Airlines
LUV
$19.5B
| $408M | 0.59% |
8,779,389
-230,436
| -3% | -$12.2M |
|
Similar funds
Boston Partners's Q4 2018 Portfolio in Review
As of Q4 2018, Boston Partners held 779 positions worth $69.6B, down 19% from $86.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Boston Partners withdrew a net $3.3B in Q4 2018, closing 76 positions and reducing 313 holdings. Its most notable exit was Andeavor, an estimated $1.05B position sold in full.
By sector, the portfolio is most concentrated in Financials at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Boston Partners opened a new position in Procter & Gamble worth $775M.
- Boston Partners's largest Q4 2018 buy was Procter & Gamble: 8,428,522 shares worth $775M.
- Boston Partners added most to Marathon Petroleum in Q4 2018, an estimated $374M increase.
- Boston Partners's biggest Q4 2018 reduction was Merck, cutting an estimated $702M.
- Boston Partners fully exited Andeavor in Q4 2018, selling an estimated $1.05B.
- Boston Partners's ten largest holdings make up 18% of its $69.6B portfolio in Q4 2018.
- Boston Partners opened 83 new positions and closed 76 in Q4 2018.
- Boston Partners's portfolio value fell 19% quarter-over-quarter to $69.6B.
Based on Boston Partners's 13F filing for Q4 2018, filed 7 Feb 2019.